Xeris Biopharma Announces Positive Topline Phase 2 Clinical Data of Its Investigational XeriSol(TM)-Formulated Once-Weekly Subcutaneous (SC) Levothyroxine (XP-8121)

Stock Information for Chiasma Inc.

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About Chiasma Inc.

Xeris Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
Xeris to Participate in Upcoming Investor Conferences
Xeris Biopharma Reports Second Quarter 2024 Financial Results
Xeris Biopharma to Report Second Quarter 2024 Financial Results on August 8, 2024
Xeris Biopharma Announces CEO Succession Plan
Xeris Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
Xeris Presents New Post Hoc Analysis on Effects of Levoketoconazole (Recorlev®) in Cushing's Syndrome Patients at ENDO 2024
Xeris to Participate in the Jefferies Global Healthcare Conference

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.